These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 21711074)

  • 1. Characterizing medical care by disease phase in metastatic colorectal cancer.
    Song X; Zhao Z; Barber B; Gregory C; Schutt D; Gao S
    Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP20-5. PubMed ID: 21711074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing medical care by disease phase in metastatic colorectal cancer.
    Song X; Zhao Z; Barber B; Gregory C; Schutt D; Gao S
    J Oncol Pract; 2011 May; 7(3 Suppl):25s-30s. PubMed ID: 21886516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents.
    Dacosta Byfield S; Yu E; Morlock R; Evans D; Teitelbaum A
    J Med Econ; 2013 Aug; 16(8):1071-81. PubMed ID: 23777222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.
    Paramore LC; Thomas SK; Knopf KB; Cragin LS; Fraeman KH
    Clin Colorectal Cancer; 2006 May; 6(1):52-8. PubMed ID: 16796792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
    Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
    Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of hospital events in patients with metastatic colorectal cancer.
    Overbeek JA; Zhao Z; van Herk-Sukel MP; Barber BL; Gao S; Herings RM
    J Med Econ; 2011; 14(5):656-61. PubMed ID: 21854190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
    Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
    J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of new chemotherapeutic agents for metastatic colorectal cancer.
    Howard DH; Kauh J; Lipscomb J
    Arch Intern Med; 2010 Mar; 170(6):537-42. PubMed ID: 20233802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
    Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
    Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
    Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
    J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outpatient cancer drug costs: changes, drivers, and the future.
    Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
    Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy for metastatic colorectal cancer].
    Iwasa S; Shimada Y
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1467-74. PubMed ID: 18799899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population.
    DaCosta Byfield S; Nash Smyth E; Mytelka D; Bowman L; Teitelbaum A
    J Med Econ; 2013 Dec; 16(12):1379-86. PubMed ID: 24074258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
    Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
    Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of illness in patients with metastatic colorectal cancer.
    Song X; Zhao Z; Barber B; Gregory C; Cao Z; Gao S
    J Med Econ; 2011; 14(1):1-9. PubMed ID: 21108534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.